Sitagliptin 100 mg Tablet (Sitagliptin Phosphate)
Sitagliptin Phosphate 124.08mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.
MFDS item code 201507870 · Approved 2015.11.25
This product's status changed to Expired on 2025.11.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in type 2 diabetes mellitus
This medication is used in combination with diet and exercise to improve blood sugar control in patients with type 2 diabetes. It may be administered alone when starting therapy, and if blood sugar control is insufficient with monotherapy, it can be used in combination with metformin. Additionally, it may be used in conjunction with sulfonylureas, thiazolidinediones, or insulin when blood sugar control is inadequate with monotherapy. Moreover, for those who are insufficiently controlled on combinations of sulfonylureas with metformin, thiazolidinediones with metformin, or insulin with metformin, this drug can be added to enhance treatment. In this way, this medication effectively improves blood sugar control at various stages of treatment.
This drug is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, evaluation of renal function is recommended before and periodically after starting treatment with this drug. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.
This medication may cause serious allergic reactions in some patients; therefore, if symptoms such as a skin rash or difficulty breathing appear within 3 months of administration, it should be discontinued immediately and a physician should be consulted. This medication can induce severe pancreatic disease known as acute pancreatitis, so symptoms such as abdominal pain or vomiting should be reported to a physician immediately. It is not for use in patients with type 1 diabetes, diabetic ketoacidosis, or those with hypersensitivity to this drug or its components. Patients with impaired renal function may experience delayed excretion of this drug; thus, dosage adjustments should be made according to a physician's directions. This medication poses a risk of hypoglycemia when taken alone or with other diabetes medications, so blood glucose should be monitored carefully, especially when used with insulin or sulfonylureas. Severe joint pain or conditions that cause blisters on the skin may occur; if such symptoms arise, the medication should be discontinued and a physician should be consulted immediately. Women who are pregnant or breastfeeding should avoid using this medication, and safety in children and adolescents under 18 years has not yet been established. Elderly patients are at a higher risk of renal function decline, so regular monitoring of renal function should be performed before and during administration. In case of overdose, measures should be taken to remove the drug from the gastrointestinal tract and clinical monitoring such as electrocardiogram should be conducted, and if necessary, certain drugs can be removed through dialysis. This medication has minimal significant interactions with other drugs; however, if taking certain medications, informing a physician and appropriate monitoring is required. Patients should report any unusual symptoms or side effects to healthcare professionals immediately.
Not everyone experiences these, and they can vary from person to person.
Store the medication in a tightly closed container to prevent air from entering, and it is recommended to keep it at a temperature between 1°C and 30°C. Proper storage helps maintain the drug's effectiveness for a longer period.
Beige, biconvex, round film-coated tablet
28 tablets (14 tablets/PTP × 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 124.08mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.